Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 7/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | NQO2 | P16083 | 1/20 | 0.45 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.45 |
| ▸ | CFTR | P13569 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1058558 | 1.00 | GSK3B (0.55) | GSK3BKMT2AMEN1NPC1GAA | |
| SCHEMBL1059295 | 0.90 | GSK3B (0.49) | GSK3BKMT2AMEN1NPC1RAB9A | |
| SCHEMBL1059298 | 0.90 | GSK3B (0.49) | GSK3BKMT2AMEN1NPC1RAB9A | |
| SCHEMBL1058014 | 0.88 | KDM4E (0.49) | GSK3BKMT2AMEN1NPC1RAB9A | |
| SCHEMBL1058015 | 0.88 | KDM4E (0.49) | GSK3BKMT2AMEN1NPC1RAB9A | |
| SCHEMBL2900205 | 0.85 | KDM4E (0.54) | GSK3BKMT2AMEN1NPC1GAA | |
| SCHEMBL1057335 | 0.85 | NR3C1 (0.46) | GSK3BMAPTHPGDKDM4EALDH1A1 | |
| SCHEMBL1057333 | 0.85 | NR3C1 (0.46) | GSK3BMAPTHPGDKDM4EALDH1A1 | |
| SCHEMBL1056358 | 0.83 | MAPT (0.49) | GSK3BKMT2AMEN1NPC1GAA | |
| SCHEMBL1056357 | 0.83 | MAPT (0.49) | GSK3BKMT2AMEN1NPC1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204251-A1 | MOLECULAR TARGET OF NEUROTOXICITY | EXONHIT THERAPEUTICS SA (FR) | 2010-08-12 | — | — | US | claimed |
| EP-1982704-B1 | New molecular target of neurotoxicity | EXONHIT THERAPEUTICS SA (FR) | 2010-08-04 | — | — | EP | claimed |
| US-20060142326-A1 | Use of pyrazolopyridines for the treatment of cognitive deficits | DIAXONHIT (FR) | 2006-06-29 | — | — | US | claimed |
| US-20050043319-A1 | Detecting neuronal stress via monitoring in vitro expression of phosphodiesterases; diagnosis, prevention and treatment of amyotrophic lateral sclerosis and other neurodegenerative diseases; drug screening | EXONHIT THERAPEUTICS SA (FR) | 2005-02-24 | — | — | US | claimed |
| US-20040219552-A1 | Novel molecular target for neurotoxicity | EXONHIT THERAPEUTICS SA (FR) | 2004-11-04 | — | — | US | claimed |
| US-20120202846-A1 | MOLECULAR TARGET OF NEUROTOXICITY | EXONHIT THERAPEUTICS SA (FR) | 2012-08-09 | — | — | US | disclosed |
| US-7872015-B2 | Methods involving PDE4, compositions, and the screening thereof, for the treatment of degenerative ocular pathologies | EXONHIT THERAPEUTICS SA (FR) | 2011-01-18 | — | — | US | disclosed |
| US-20100204251-A1 | MOLECULAR TARGET OF NEUROTOXICITY | EXONHIT THERAPEUTICS SA (FR) | 2010-08-12 | — | — | US | disclosed |
| EP-1982704-B1 | New molecular target of neurotoxicity | EXONHIT THERAPEUTICS SA (FR) | 2010-08-04 | — | — | EP | disclosed |
| EP-1417349-B1 | NOVEL MOLECULAR TARGET FOR NEUROTOXICITY | EXONHIT THERAPEUTICS SA (FR) | 2008-11-19 | — | — | EP | disclosed |
| EP-1982704-A2 | New molecular target of neurotoxicity | Exonhit Therapeutics SA (FR) | 2008-10-22 | — | — | EP | disclosed |
| US-20060241062-A1 | Method involving pde4, compositions, and the screening thereof, for the treatment of degenerative ocular pathologies | EXONHIT THERAPEUTICS SA (FR) | 2006-10-26 | — | — | US | disclosed |
| US-20060142326-A1 | Use of pyrazolopyridines for the treatment of cognitive deficits | DIAXONHIT (FR) | 2006-06-29 | — | — | US | disclosed |
| US-20050043319-A1 | Detecting neuronal stress via monitoring in vitro expression of phosphodiesterases; diagnosis, prevention and treatment of amyotrophic lateral sclerosis and other neurodegenerative diseases; drug screening | EXONHIT THERAPEUTICS SA (FR) | 2005-02-24 | — | — | US | disclosed |
| US-20040219552-A1 | Novel molecular target for neurotoxicity | EXONHIT THERAPEUTICS SA (FR) | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043319-A1 | Detecting neuronal stress via monitoring in vitro expression of phosphodiesterases; diagnosis, prevention and treatment of amyotrophic lateral sclerosis and other neurodegenerative diseases; drug screening | PDE4B, PDE4A, PDE4D | GSK3B 701/4885KMT2A 2147/4885MEN1 4425/4885 |
| US-20120202846-A1 | MOLECULAR TARGET OF NEUROTOXICITY | PDE4B, TDP2, PDE4A | GSK3B 807/4885KMT2A 1469/4885MEN1 4671/4885 |
| US-20060241062-A1 | Method involving pde4, compositions, and the screening thereof, for the treatment of degenerative ocular pathologies | PDE4B, PDE4A, GABRA4 | GSK3B 353/4885KMT2A 2024/4885MEN1 4415/4885 |
| US-20060142326-A1 | Use of pyrazolopyridines for the treatment of cognitive deficits | QDPR, ACHE, GRN | GSK3B 897/4885KMT2A 1737/4885MEN1 3709/4885 |
| US-20100204251-A1 | MOLECULAR TARGET OF NEUROTOXICITY | PDE4B, TDP2, PDE4A | GSK3B 807/4885KMT2A 1469/4885MEN1 4671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.